Developer docs
API playgroundTry for free, no card

Search company profiles

Serenatis Bio

Full company profile

uuid00sad22

Namestring
Serenatis Bio
Legal namestring
Serenatis Bio
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Serenatis Bio is a privately held, pre-clinical biotechnology company founded in 2024 and headquartered in Cambridge, United Kingdom. The company is developing a pipeline of three novel small-molecule drug candidates that target glutamate and dopamine pathways to treat obsessive-compulsive disorder (OCD), a condition the company frames as affecting an estimated 240 million people worldwide and imposing £10.7 billion in economic and healthcare costs on the UK alone. The pipeline is positioned against documented limitations of current standard of care — SSRIs, tricyclic antidepressants, and antipsychotics — including slow onset (months), significant side effects, and high rates of residual symptomatology, alongside limited access to cognitive behavioral therapy with high dropout rates.

The drug discovery program is built on AI and computational methods spanning biotechnology, bioinformatics, and computational biomedical engineering, used to accelerate lead identification and optimization and to tailor candidates to individual neurobiological profiles under a precision medicine framework. Scientific oversight is provided by Prof Trevor Robbins (Professor of Cognitive Neuroscience and Director of the Behavioural and Clinical Neurosciences Institute at Cambridge, Fellow of the Royal Society) and Prof Jon Grant (Professor of Psychiatry at University of Chicago, specialising in compulsive and impulsive disorders). Pre-clinical execution is delivered through dedicated CRO relationships with Sygnature Discovery, o2h discovery, and GeN.DDi.

The company is pre-revenue and intends to monetize through out-licensing or partnership with larger pharmaceutical companies for clinical development and commercialization, with future royalty streams. It is venture-backed by Zinc VC, p53, and Novaterra and is currently advancing a 2026 funding round. Headcount is in the 11-50 range under the leadership of CEO and co-founder David Cavalla (35 years of pharma industry experience, formerly founder and CEO of Arachnova Ltd) and Executive Chairman and co-founder Nick Sireau (OCD patient advocate with prior regulatory approval experience in rare disease drug development).

Short descriptiontext

Serenatis Bio is a pre-clinical Cambridge, UK biotechnology company developing three novel small-molecule drug candidates that target glutamate and dopamine pathways for obsessive-compulsive disorder, using AI-driven drug discovery and a planned licensing-based commercialization model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small-molecule drug discovery, OCD therapeutics, neuropsychiatric drug development, computational drug discovery, central nervous system pharmaceuticals
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
OCD Therapeutics (Pre-clinical neuropsychiatric pharmaceuticals)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Future Drug Licensing/Royalties
TypeLicensing Royalties
Description

Pre-revenue biotech company. Future revenue anticipated from licensing novel OCD therapeutics to pharmaceutical partners or through acquisition. Three drug candidates in development targeting glutamate and dopamine pathways.

serenatisbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Serenatis Bio is a pre-clinical biotechnology company developing three novel small-molecule drug candidates with unique mechanisms of action that target glutamate and dopamine neural pathways to treat obsessive-compulsive disorder (OCD). The company applies AI-driven computational methods, bioinformatics, and computational biomedical engineering to accelerate discovery, with a precision medicine approach tailoring each candidate to individual neurobiological profiles. The pipeline is currently pre-clinical and is advancing toward clinical studies, with anticipated future commercialization via licensing or partnership with larger pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Global OCD prevalence: 240 million people affected worldwide
+2 more records
Product overview1 text field

Serenatis Bio is a biotech company developing a pipeline of three novel small-molecule drug candidates targeting glutamate and dopamine pathways for obsessive-compulsive disorder (OCD) treatment. The three unique candidates represent a unified therapeutic approach aimed at addressing the pathophysiological underpinnings of OCD through precision medicine, with each candidate tailored to individual neurobiological profiles.

Product and service1 record
1Pipeline of three novel small-molecule OCD drug candidates
CategoryOCD Therapeutics / Neuropsychiatric Pharmaceuticals
Description

A pre-clinical pipeline of three proprietary small-molecule drug candidates, each with a distinct mechanism of action targeting glutamate and dopamine neural pathways, developed for the treatment of obsessive-compulsive disorder and intended for future out-licensing, partnership, or acquisition by pharmaceutical companies for clinical development and commercialization.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading integrated drug discovery partner and contract research organisation (CRO) specialising in high-quality research and expertise within the neuroscience specialty for Serenatis Bio's drug development program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Integrated drug discovery CRO specialising in medicinal chemistry and lead optimisation. Co-hosted Cambridge X London Life Sciences Showcase where Serenatis pitched.

3GeN.DDi
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Specialised neuroscience contract research organisation (CRO) focusing on translational in vivo pharmacology for proof of concept studies.

serenatisbio.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Globally recognised law firm with expertise spanning life sciences, biotechnology and pharmaceutical companies providing legal support.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based AI drug discovery company using machine learning to identify novel therapeutic targets and small molecules. Geographic and methodological peer based in the UK life sciences ecosystem applying AI to CNS and other indications.

TypeBroad incumbent
Description

Specialty pharma dedicated to brain diseases with active CNS pipelines and commercial infrastructure in psychiatric indications. A likely licensing/BD counterparty for Serenatis and a competing developer of OCD therapies.

TypeDirect peer
Description

AI-driven small-molecule drug discovery company using computational methods to accelerate candidate design across multiple therapeutic areas. Directly comparable on the AI/computational drug discovery platform that Serenatis employs for its OCD pipeline.

TypeDirect peer
Description

Clinical-stage biotech developing precision medicines for brain diseases with OCD as a stated focus area (e.g., NMRA-140). Directly comparable as a CNS-focused therapeutics developer targeting underserved psychiatric conditions.

TypeEmerging player
Description

Mental health-focused biopharma developing innovative therapies for treatment-resistant psychiatric conditions including OCD. Comparable as a developer targeting underserved neuropsychiatric populations with novel mechanism approaches.

TypeEmerging player
Description

AI-driven drug discovery platform combining generative chemistry and target identification to develop novel therapeutics. Comparable on the AI-first discovery methodology applied to small-molecule drug development.

TypeBroad incumbent
Description

Biopharma developing CNS medicines with neurology and psychiatry focus. Overlaps in CNS pipeline strategy and target underserved psychiatric patient populations similar to Serenatis's OCD thesis.

TypeDirect peer
Description

AI-enabled drug discovery company using computational biology and machine learning to identify novel therapeutics at scale. Comparable as a platform-based drug discovery company employing AI methods to drive preclinical asset generation.

TypeBroad incumbent
Description

Established CNS-focused pharma with approved treatments in adjacent psychiatric space and pipeline assets in OCD-related indications. Directly competes for the same prescriber base in OCD treatment.

TypeBroad incumbent
Description

Neuroscience-focused clinical-stage biopharma developing therapies for brain and nervous system disorders. Shares the precision-neuroscience strategic positioning targeting psychiatric conditions.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Serenatis Bio

OCD Therapeutics (Pre-clinical neuropsychiatric pharmaceuticals)serenatisbio.com

Serenatis Bio is a pre-clinical Cambridge, UK biotechnology company developing three novel small-molecule drug candidates that target glutamate and dopamine pathways for obsessive-compulsive disorder, using AI-driven drug discovery and a planned licensing-based commercialization model.

What Serenatis Bio does

Serenatis Bio is a privately held, pre-clinical biotechnology company founded in 2024 and headquartered in Cambridge, United Kingdom. The company is developing a pipeline of three novel small-molecule drug candidates that target glutamate and dopamine pathways to treat obsessive-compulsive disorder (OCD), a condition the company frames as affecting an estimated 240 million people worldwide and imposing £10.7 billion in economic and healthcare costs on the UK alone. The pipeline is positioned against documented limitations of current standard of care — SSRIs, tricyclic antidepressants, and antipsychotics — including slow onset (months), significant side effects, and high rates of residual symptomatology, alongside limited access to cognitive behavioral therapy with high dropout rates.

The drug discovery program is built on AI and computational methods spanning biotechnology, bioinformatics, and computational biomedical engineering, used to accelerate lead identification and optimization and to tailor candidates to individual neurobiological profiles under a precision medicine framework. Scientific oversight is provided by Prof Trevor Robbins (Professor of Cognitive Neuroscience and Director of the Behavioural and Clinical Neurosciences Institute at Cambridge, Fellow of the Royal Society) and Prof Jon Grant (Professor of Psychiatry at University of Chicago, specialising in compulsive and impulsive disorders). Pre-clinical execution is delivered through dedicated CRO relationships with Sygnature Discovery, o2h discovery, and GeN.DDi.

The company is pre-revenue and intends to monetize through out-licensing or partnership with larger pharmaceutical companies for clinical development and commercialization, with future royalty streams. It is venture-backed by Zinc VC, p53, and Novaterra and is currently advancing a 2026 funding round. Headcount is in the 11-50 range under the leadership of CEO and co-founder David Cavalla (35 years of pharma industry experience, formerly founder and CEO of Arachnova Ltd) and Executive Chairman and co-founder Nick Sireau (OCD patient advocate with prior regulatory approval experience in rare disease drug development).

Serenatis Bio firmographics

Firmographics
Name
Serenatis Bio
Legal name
Serenatis Bio
Website
https://serenatisbio.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
1–10 employees
Short description
Serenatis Bio is a pre-clinical Cambridge, UK biotechnology company developing three novel small-molecule drug candidates that target glutamate and dopamine pathways for obsessive-compulsive disorder, using AI-driven drug discovery and a planned licensing-based commercialization model.
Ownership category
akta.pro rank

Serenatis Bio industry classification

Industry
Product category
OCD Therapeutics (Pre-clinical neuropsychiatric pharmaceuticals)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Small-molecule drug discovery
  • OCD therapeutics
  • Neuropsychiatric drug development
  • Computational drug discovery
  • Central nervous system pharmaceuticals

Where Serenatis Bio is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Serenatis Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Future Drug Licensing/Royalties: Pre-revenue biotech company. Future revenue anticipated from licensing novel OCD therapeutics to pharmaceutical partners or through acquisition. Three drug candidates in development targeting glutamate and dopamine pathways.

Go-to-market motion1 record

Marketing channels5 records

Serenatis Bio product offering

Product offering

Core offering

Serenatis Bio is a pre-clinical biotechnology company developing three novel small-molecule drug candidates with unique mechanisms of action that target glutamate and dopamine neural pathways to treat obsessive-compulsive disorder (OCD). The company applies AI-driven computational methods, bioinformatics, and computational biomedical engineering to accelerate discovery, with a precision medicine approach tailoring each candidate to individual neurobiological profiles. The pipeline is currently pre-clinical and is advancing toward clinical studies, with anticipated future commercialization via licensing or partnership with larger pharmaceutical companies.

Product overview

Serenatis Bio is a biotech company developing a pipeline of three novel small-molecule drug candidates targeting glutamate and dopamine pathways for obsessive-compulsive disorder (OCD) treatment. The three unique candidates represent a unified therapeutic approach aimed at addressing the pathophysiological underpinnings of OCD through precision medicine, with each candidate tailored to individual neurobiological profiles.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pipeline of three novel small-molecule OCD drug candidates A pre-clinical pipeline of three proprietary small-molecule drug candidates, each with a distinct mechanism of action targeting glutamate and dopamine neural pathways, developed for the treatment of obsessive-compulsive disorder and intended for future out-licensing, partnership, or acquisition by pharmaceutical companies for clinical development and commercialization.

Quantifiable outcome

  • Global OCD prevalence: 240 million people affected worldwide
  • +2 more outcomes

Companies that use Serenatis Bio

Customer profile

Segments1 record

Ideal customer profiles1 record

Serenatis Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Serenatis Bio partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Sygnature DiscoverycoreStrategic or Co-development PartnerLeading integrated drug discovery partner and contract research organisation (CRO) specialising in high-quality research and expertise within the neuroscience specialty for Serenatis Bio's drug development program.
  • o2h discoverycoreStrategic or Co-development PartnerIntegrated drug discovery CRO specialising in medicinal chemistry and lead optimisation. Co-hosted Cambridge X London Life Sciences Showcase where Serenatis pitched.
  • GeN.DDicoreStrategic or Co-development PartnerSpecialised neuroscience contract research organisation (CRO) focusing on translational in vivo pharmacology for proof of concept studies.
  • GoodwinminorImplementation/ SI/ Consulting PartnerGlobally recognised law firm with expertise spanning life sciences, biotechnology and pharmaceutical companies providing legal support.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Serenatis Bio competitors and assessment

Company assessment

Direct peers

  • BenevolentAI: UK-based AI drug discovery company using machine learning to identify novel therapeutic targets and small molecules. Geographic and methodological peer based in the UK life sciences ecosystem applying AI to CNS and other indications.
  • Exscientia: AI-driven small-molecule drug discovery company using computational methods to accelerate candidate design across multiple therapeutic areas. Directly comparable on the AI/computational drug discovery platform that Serenatis employs for its OCD pipeline.
  • Neumora Therapeutics: Clinical-stage biotech developing precision medicines for brain diseases with OCD as a stated focus area (e.g., NMRA-140). Directly comparable as a CNS-focused therapeutics developer targeting underserved psychiatric conditions.
  • Recursion Pharmaceuticals: AI-enabled drug discovery company using computational biology and machine learning to identify novel therapeutics at scale. Comparable as a platform-based drug discovery company employing AI methods to drive preclinical asset generation.

Broad incumbents

  • Lundbeck: Specialty pharma dedicated to brain diseases with active CNS pipelines and commercial infrastructure in psychiatric indications. A likely licensing/BD counterparty for Serenatis and a competing developer of OCD therapies.
  • Sage Therapeutics: Biopharma developing CNS medicines with neurology and psychiatry focus. Overlaps in CNS pipeline strategy and target underserved psychiatric patient populations similar to Serenatis's OCD thesis.
  • Acadia Pharmaceuticals: Established CNS-focused pharma with approved treatments in adjacent psychiatric space and pipeline assets in OCD-related indications. Directly competes for the same prescriber base in OCD treatment.
  • Biohaven Ltd: Neuroscience-focused clinical-stage biopharma developing therapies for brain and nervous system disorders. Shares the precision-neuroscience strategic positioning targeting psychiatric conditions.

Emerging players

  • Compass Pathways: Mental health-focused biopharma developing innovative therapies for treatment-resistant psychiatric conditions including OCD. Comparable as a developer targeting underserved neuropsychiatric populations with novel mechanism approaches.
  • Insilico Medicine: AI-driven drug discovery platform combining generative chemistry and target identification to develop novel therapeutics. Comparable on the AI-first discovery methodology applied to small-molecule drug development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Serenatis Bio social profiles

Digital presence

Serenatis Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Serenatis Bio leadership team

Management profile

Number of profiles

Profiles9 records

Serenatis Bio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Serenatis Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Serenatis Bio

What does Serenatis Bio do?

Serenatis Bio is a pre-clinical biotechnology company developing three novel small-molecule drug candidates with unique mechanisms of action that target glutamate and dopamine neural pathways to treat obsessive-compulsive disorder (OCD). The company applies AI-driven computational methods, bioinformatics, and computational biomedical engineering to accelerate discovery, with a precision medicine approach tailoring each candidate to individual neurobiological profiles. The pipeline is currently pre-clinical and is advancing toward clinical studies, with anticipated future commercialization via licensing or partnership with larger pharmaceutical companies.

Is Serenatis Bio a public or private company?

Serenatis Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Serenatis Bio founded?

Serenatis Bio was founded in 2024. It employs 1 to 10 people.

Where is Serenatis Bio based?

Serenatis Bio is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Serenatis Bio make money?

One revenue line is on record: future Drug Licensing/Royalties.

Who are Serenatis Bio's main competitors?

Direct peers on record are BenevolentAI, Exscientia, Neumora Therapeutics and Recursion Pharmaceuticals. Broad incumbents are Lundbeck, Sage Therapeutics, Acadia Pharmaceuticals and Biohaven Ltd. Emerging players are Compass Pathways and Insilico Medicine.

Does Serenatis Bio have an API?

No public API is recorded for Serenatis Bio.

What industry is Serenatis Bio in?

Serenatis Bio's product category is OCD Therapeutics (Pre-clinical neuropsychiatric pharmaceuticals). Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals